Albert David Limited is a pharmaceutical company built on a rare biological niche: it is the sole worldwide supplier of a placenta-extract therapy and a critical anti-leishmaniasis injection, giving it monopoly positions in tiny but essential corners of medicine. Incorporated in 1938 and headquartered in Kolkata as the flagship of the Kothari Group, the company has spent over eight decades refining the science of human placenta extract while also manufacturing a broad range of acute-care formulations and intravenous fluids. The recurring approach is to own the entire chain-from procuring raw placentae from government hospitals and running a government-recognised R&D lab, to manufacturing in two plants and selling through a specialty-focused field force-so that the know-how stays inside the company and the barriers to entry stay high. # Business segments Two engines that share the same manufacturing backbone and sales force, but are fundamentally different businesses-a monopoly supplier of niche biologic drugs to the world, and a domestic formulations house that sells acute-care medicines to Indian doctors through five specialty sales teams. ## 1. Niche biologic drugs: the world's sole supplier for two life-saving therapies **The company holds a global monopoly on Sodium Stibogluconate Injection and Placentrex, drugs that treat a neglected tropical disease and hard-to-heal wounds respectively-no competitor can make them.** - **Sole supplier for SSG and Placentrex worldwide** - Albert David is the only manufacturer in the world producing Sodium Stibogluconate (SSG) Injection, the medicine used to combat visceral leishmaniasis, also known as Kala-azar. It also makes Miltefosine Capsules, a second anti-leishmaniasis drug, and has built a dedicated manufacturing facility at its Kolkata plant to produce Miltefosine to WHO standards, which opens the door to supplying global health programmes. - **Placenta extract as a moat** - the Placentrex range, derived from human placenta extract, is used by gynaecologists for pelvic inflammatory disease and by surgeons for wounds that refuse to heal, and the company is the sole worldwide supplier. The raw material comes from approved government hospitals under cold-chain monitoring, a sourcing arrangement that is difficult for anyone else to replicate at scale. - **Science that deepens the monopoly** - the R&D centre, recognised by the Department of Scientific and Industrial Research since 2013, focuses on placenta-extract research and its combination with other therapeutic compounds, and has filed a provisional patent for the therapeutic components and preparation process. A collaborative project with IIT-Kharagpur's Department of Biotechnology is investigating exactly how Placentrex inhibits bacterial growth, and the Drug Controller General of India has approved the inclusion of bio-constituents on the label-both moves that make the product harder to copy. - **Co-marketing to widen the reach** - in 2021, the company signed a strategic co-marketing agreement with Corona Remedies Private Limited to sell the Placentrex range under a second brand name, putting its monopoly product into a larger sales network without giving up manufacturing control. ## 2. Domestic acute-care formulations: a specialty sales engine selling to Indian doctors **A portfolio of tablets, capsules, injections, ointments and syrups sold through five doctor-specialty-focused field forces, with a recent push into gynaecology and orthopaedics.** - **Five specialty sales forces** - the company restructured its domestic field operations into separate sales teams, each calling on a different doctor specialty, expanding from three forces in FY24 to five by FY25 so that a gynaecologist and an orthopaedic surgeon each hear a focused product story. The field force sells through stockists to both government and non-government customers, with sales depots in six cities: Bhopal, Delhi, Kolkata, Lucknow, Mumbai, and Patna. - **Acute-care only, no chronic** - the entire business sits in the acute segment of the pharmaceutical market, meaning it sells medicines for short-term conditions rather than lifelong therapies, which makes demand tied to illness episodes and doctor prescriptions. - **New launches in women's health and joint care** - in FY25, the company launched seven new products in gynaecology, including Alamin woman and Vaginova, and four in orthopaedics, including C3H OA Tabs and DhupCal Tabs, signalling a deliberate push into these two specialties. An earlier acquisition of the trademark 'EVACURE' from Alkem Laboratories gave it a brand used by gynaecologists for PCOS management. - **Amino acids and IV fluids as the backbone** - the company pioneered Amino Acids group products in infusion and capsule form for malnutrition and pre- and post-operative support, and IV fluids are one of its three key product pillars alongside Placentrex and Evict. The portfolio spans large-volume and small-volume parenterals, which are the sterile solutions administered directly into the bloodstream in hospitals. # Exports: a small but growing international footprint **The company sells to over fifteen countries across Latin America, South-East Asia and Africa, and is now investing in regulatory filings to register more products in those markets.** - **Wide geography, thin presence** - export markets include Myanmar, Philippines, Vietnam, Kazakhstan, Uzbekistan, Peru, Ethiopia, Tanzania, Nigeria and several others, but the business remains a small part of the whole. The company operates as a single business segment that cannot be split by geography, so exports are managed from the same manufacturing and R&D base. - **Regulatory push as the growth lever** - the company has stepped up regulatory activities to register more products in existing markets and is seeking collaboration with established partners to accelerate exports in South-East Asia and CIS countries, because each new product registration in a country unlocks a new revenue stream. # R&D and manufacturing backbone **Two plants and a government-recognised R&D lab that develop everything from placenta-extract science to energy-efficient manufacturing processes.** - **Two factories, one R&D hub** - manufacturing takes place at plants in Kolkata and Ghaziabad, while the R&D centre in Kolkata handles formulation and API development, process optimisation, and regulatory dossier preparation for both domestic and export markets. The R&D team also supports production, quality control and quality assurance teams across early and late-stage product development. - **External collaborations that multiply capability** - the company works with CSIR, IITs, IISc, DST and DRDO, as well as entities in the US and EU, to develop drug products, which gives it access to scientific expertise beyond its own walls. National research institutes and universities are also involved in expanding the therapeutic applications of placenta extract. - **Energy cost as a competitive lever** - at the Kolkata plant, a circulation system along with a cooling tower system saves about one lakh litres of water per day, and a new high-efficiency electric chiller replaced three old steam-operated ones. At Ghaziabad, a dedicated power feeder cut diesel consumption by 22%, and the plant began receiving solar power in April 2025 through an investment in a captive solar producer, which directly reduces the cost of running the factory. # Group structure and partners **A standalone company with no subsidiaries or joint ventures, but with strategic co-marketing ties and a captive solar investment that lowers factory power costs.** - **Flagship of the Kothari Group, but no corporate layers** - Albert David is the group's flagship company and has no subsidiaries, joint ventures or associate companies, which means all operations sit inside one listed entity. - **Captive solar to cut power bills** - the company subscribed to equity shares of Sunsure Solarpark Five Private Limited, a renewable-energy generator, to secure captive solar power for its Ghaziabad plant under the Electricity Act, with an investment of up to INR 78.75 lakhs. - **Co-marketing and brand acquisitions** - the Placentrex co-marketing agreement with Corona Remedies and the acquisition of the 'EVACURE' trademark from Alkem Laboratories are the two key external partnerships that extend the company's commercial reach without adding operational complexity. - **Industry associations** - the company is a member of the Indian Pharmaceuticals Alliance, the Bulk Drug Manufacturers Association, the Indian Drug Manufacturing Association and the Pharmaceuticals Export Promotion Council, connecting it to policy and trade networks.